
Laura March

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7931952/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea: A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui). Clinical Infectious Diseases, 2021, 73, 2166-2174.	5.8	12
2	Intimate partner violence by men living with HIV in Cameroon: Prevalence, associated factors and implications for HIV transmission risk (ANRS-12288 EVOLCAM). PLoS ONE, 2021, 16, e0246192.	2.5	4
3	Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study. Lancet Microbe, The, 2021, 2, e676-e684.	7.3	10
4	Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity—results from the ANRS-12288 EVOLCam survey. Women's Health, 2019, 15, 174550651984854.	1.5	19
5	A 40 months follow-up of Ebola virus disease survivors in Guinea (Postebogui)Âreveals longterm detection of Ebola viral RNA in semen and breast milk. Open Forum Infectious Diseases, 2019, 6, ofz482.	0.9	26
6	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	3.0	7
7	Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (<scp>ANRS</scp> 12288 <scp>EVOLCAM</scp>). HIV Medicine, 2019, 20, 38-46.	2.2	9
8	Treatment interruption in <scp>HIV</scp> â€positive patients followed up in Cameroon's antiretroviral treatment programme: individual and health care supplyâ€related factors (<scp>ANRS</scp> â€12288) Tj ETQq0	0 23 3gBT /	O ve rlock 10
9	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	4.7	187
10	Discussing HIV Status: Is It Easier After 10ÂYears of Antiretroviral Treatment? The ANRS CO8 APROCO-COPILOTE Cohort. AIDS and Behavior, 2017, 21, 118-128.	2.7	2
11	Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infectious Diseases, The, 2017, 17, 545-552.	9.1	96
12	Characteristics of the musculoskeletal symptoms observed among survivors of Ebola virus disease in the Postebogui cohort in Guinea. Rheumatology, 2017, 56, 2068-2072.	1.9	17
13	Chlamyweb Study II: a randomised controlled trial (RCT) of an online offer of home-based <i>Chlamydia trachomatis</i> sampling in France. Sexually Transmitted Infections, 2017, 93, 188-195.	1.9	37
14	Ocular Complications in Survivors of the Ebola Outbreak in Guinea. American Journal of Ophthalmology, 2017, 175, 114-121.	3.3	55
15	Reply. American Journal of Ophthalmology, 2017, 181, 180.	3.3	0
16	Depressive symptoms among survivors of Ebola virus disease in Conakry (Guinea): preliminary results of the PostEboGui cohort. BMC Psychiatry, 2017, 17, 127.	2.6	75
17	Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus. Journal of Clinical Microbiology, 2017, 55, 165-176.	3.9	47
18	Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health. Clinical Microbiology and Infection, 2017, 23, 412-413.	6.0	12

Laura March

#	Article	IF	CITATIONS
19	Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients. Aids, 2015, 29, 1105-1109.	2.2	8
20	Patterns of adherence to antiretroviral therapy and <scp>HIV</scp> drug resistance over time in the <scp>S</scp> tratall <scp>ANRS</scp> 12110/ <scp>ESTHER</scp> trial in <scp>C</scp> ameroon. HIV Medicine, 2014, 15, 478-487.	2.2	44
21	Intimate partner violence among adolescents and young women: prevalence and associated factors in nine countries: a cross-sectional study. BMC Public Health, 2014, 14, 751.	2.9	259
22	Low Alcohol Consumption as a Predictor of Higher CD4+ Cell Count in HIV-Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e148-e150.	2.1	16
23	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infectious Diseases, The, 2013, 13, 577-586.	9.1	39